Actively Recruiting
Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer
Led by Anhui Provincial Hospital · Updated on 2024-10-15
70
Participants Needed
1
Research Sites
312 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This project is an open, single-center, prospective study aimed at developing high-sensitivity, high-specificity enrichment SERS chips using femtosecond laser processing technology. It involves extracting information from blood samples of ovarian cancer patients and normal controls, specifically identifying cancer and non-cancer signals. The study will construct a statistical algorithm model for the early diagnosis of ovarian cancer, enabling early identification and intervention for ovarian cancer patients.
CONDITIONS
Official Title
Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects must understand the trial, sign informed consent, voluntarily participate, and follow the protocol
- Aged between 18 and 70 years inclusive
- Ovarian cancer patients (high-grade serous, low-grade serous, endometrioid, clear cell carcinoma) receiving initial treatment with complete clinical data
- ECOG performance status score of 0 to 3 and life expectancy over 6 months
- Consent to blood sample collection for SERS analysis
- Good organ function
- Normal controls undergoing surgery for benign diseases with complete clinical data and no prior radical treatment for the benign lesion before blood collection
You will not qualify if you...
- Severe or uncontrolled diseases including uncontrollable nausea/vomiting, gastrointestinal diseases affecting drug absorption/metabolism, mental illnesses impairing consent ability, severe cardiovascular disease, infectious diseases (syphilis, AIDS, active hepatitis B or C), abscesses, or active rheumatic diseases
- Blood transfusion within 4 weeks prior to study
- Pregnant, postpartum, breastfeeding, or planning pregnancy during study
- History of other tumors
- Investigator's judgment deeming subject unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Provincal Hospital
Hefei, Anhui, China
Actively Recruiting
Research Team
Y
Ying Zhou, MD
CONTACT
Y
Ying Zhou, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here